Literature DB >> 25243

Evidence for quantitative variability of bacterial opsonic requirements.

J C Guckian, W D Christensen, D P Fine.   

Abstract

We studied human serum opsonins by using combinations of heat inactivation and chelation to inhibit complement, adsorption to remove antibody, and trypan blue to inactivate the C3 receptor of human polymorphonuclear leukocytes. Streptococcus pneumoniae, serotype 25, required both complement and immunoglobulin for opsonization, even though that strain activated the alternative complement pathway. Both strains of Escherichia coli required antibody and complement, but varied in the degree of dependence on the C3 opsonin, since trypan blue moderately inhibited the killing of E. coli-1 and markedly inhibited the killing of E. coli-2. Serratia marcescens was opsonized in heat-inactivated serum (limited complement) or serum absorbed at 0 degrees C with S. marcescens (limited antibody), but depended on the C3 receptor in absorbed serum. S. marcescens activated the alternative pathway. Thus, opsonic requirements varied with the availability of opsonins. Requirements for bacterial opsonization vary with species and strains within species, perhaps reflecting quantitative relationships among alternative and classical pathway activation of C3, efficiency of adsorption of C3 or immunoglobulin G to bacterial surfaces, and efficiency of attachment of these ligands to polymorphonuclear leukocyte receptors. Furthermore, although not always sufficient for opsonization, the C3 opsonin (activated through either the classical or alternative pathway) appears necessary for effective phagocytosis and killing of all strains studied.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 25243      PMCID: PMC422262          DOI: 10.1128/iai.19.3.822-826.1978

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  22 in total

1.  Pneumococcal type-associated variability in alternate complement pathway activation.

Authors:  D P Fine
Journal:  Infect Immun       Date:  1975-10       Impact factor: 3.441

2.  Different roles of IgG and complement receptors in phagocytosis by polymorphonuclear leukocytes.

Authors:  B Mantovani
Journal:  J Immunol       Date:  1975-07       Impact factor: 5.422

3.  Antimicrobial mechanisms in neutrophilic polymorphonuclear leukocytes.

Authors:  S J Klebanoff
Journal:  Semin Hematol       Date:  1975-04       Impact factor: 3.851

4.  Oxidative bactericidal mechanisms of polymorphonuclear leukocytes.

Authors:  L R DeChatelet
Journal:  J Infect Dis       Date:  1975-03       Impact factor: 5.226

5.  Staphylococcal heat-stable opsonins.

Authors:  D W Humphreys; L J Wheat; A White
Journal:  J Lab Clin Med       Date:  1974-07

6.  Host resistance to Serratia marcescens infection: serum bactericidal activity and phagocytosis by normal blood leukocytes.

Authors:  M S Simberkoff; I Ricupero; J J Rahal
Journal:  J Lab Clin Med       Date:  1976-02

7.  Neutrophil receptors for IgG and complement: their roles in the attachment and ingestion phases of phagocytosis.

Authors:  D J Scribner; D Fahrney
Journal:  J Immunol       Date:  1976-04       Impact factor: 5.422

8.  Comparison of ethyleneglycoltetraacetic acid and its magnesium salt as reagents for studying alternative complement pathway function.

Authors:  D P Fine
Journal:  Infect Immun       Date:  1977-04       Impact factor: 3.441

9.  Studies of the macrophage complement receptor. Alteration of receptor function upon macrophage activation.

Authors:  C Bianco; F M Griffin; S C Silverstein
Journal:  J Exp Med       Date:  1975-06-01       Impact factor: 14.307

10.  Characterization of the macrophage receptro for complement and demonstration of its functional independence from the receptor for the Fc portion of immunoglobulin G.

Authors:  F M Griffin; C Bianco; S C Silverstein
Journal:  J Exp Med       Date:  1975-06-01       Impact factor: 14.307

View more
  13 in total

1.  Alternate complement pathway activation by group A streptococci: role of M-protein.

Authors:  A L Bisno
Journal:  Infect Immun       Date:  1979-12       Impact factor: 3.441

2.  Pneumococcal intracellular killing is abolished by polysaccharide despite serum complement activity.

Authors:  J E Schweinle
Journal:  Infect Immun       Date:  1986-12       Impact factor: 3.441

3.  Early clearance of pneumococci from the lungs of decomplemented rats.

Authors:  S R Rehm; J D Coonrod
Journal:  Infect Immun       Date:  1982-04       Impact factor: 3.441

4.  Influence of serum concentration on opsonization by the classical and alternative complement pathways.

Authors:  R W Tofte; P K Peterson; Y Kim; P G Quie
Journal:  Infect Immun       Date:  1980-02       Impact factor: 3.441

5.  Enhanced endotoxin clearance in reversed Eck fistula rats during a tolerant stage.

Authors:  Y Yamaguchi; K Mori; H Gans; M Akagi
Journal:  Jpn J Surg       Date:  1986-05

6.  Opsonizing antibodies against pneumococci detected by enhanced NBT. Reduction of phagocytizing granulocytes.

Authors:  T Urban; C Jarstrand; G Tunevall
Journal:  Infection       Date:  1982 Sep-Oct       Impact factor: 3.553

7.  Requirements of immunoglobulin and the classical and alternative complement pathways for phagocytosis and intracellular killing of multiple strains of Gram-negative aerobic bacilli.

Authors:  P Leist-Welsh; A B Bjornson
Journal:  Infect Immun       Date:  1979-10       Impact factor: 3.441

8.  Human neutrophil chemotactic response to group A streptococci: bacteria-mediated interference with complement-derived chemotactic factors.

Authors:  D E Wexler; R D Nelson; P P Cleary
Journal:  Infect Immun       Date:  1983-01       Impact factor: 3.441

9.  Trypan blue inhibition of complement receptor function on various cells.

Authors:  B L Harper; D P Fine; J C Guckian; T Cavallo
Journal:  Immunology       Date:  1981-01       Impact factor: 7.397

10.  Opsonization of four Bacteroides species: role of the classical complement pathway and immunoglobulin.

Authors:  R W Tofte; P K Peterson; D Schmeling; J Bracke; Y Kim; P G Quie
Journal:  Infect Immun       Date:  1980-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.